Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression
Clinical trial NCT03872206 · COMPLETED
Trial details
- NCT number
- NCT03872206
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-16
- Primary completion
- 2023-01-04
- Enrollment
- 95
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.